After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
Rhythm Pharmaceuticals Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Rhythm Pharmaceuticals Inc is $3.35B. A total of 0.74 million shares were traded on the day, compared to an average of 505.96K shares.
Insider Activity
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, RYTM has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 0 BUYs and 0 SELLs from insiders. Insiders purchased 0 shares during that period but sold 0.
In the most recent transaction, Smith Hunter C sold 2,215 shares of RYTM for 57.22 per share on Feb 19 ’25. After the transaction, the Chief Financial Officer now owns 109,929 company shares. In a previous transaction on Feb 19 ’25, Shulman Joseph sold 1,228 shares at 57.22 per share. RYTM shares that Chief Technical Officer owns now total 8,509.
Among the insiders who sold shares, Meeker David P disposed of 9,896 shares on Feb 19 ’25 at a per-share price of $57.22. This resulted in the President and CEO holding 201,281 shares of RYTM after the transaction. In another insider transaction, Lee Jennifer Kayden sold 2,035 shares at $57.22 per share on Feb 19 ’25. Company shares held by the EVP, Head of North America now total 5,858.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for RYTM in the last 3 months, the mean price target is $75.08 with high estimates of $94.00 and low estimates of $60.00. In terms of 52-week highs and lows, RYTM has a high of $68.58 and a low of $35.17.
As of this writing, RYTM has an earnings estimate of -$0.66 per share for the current quarter. EPS was calculated based on a consensus of 8.0 estimates, with a high estimate of -$0.51 per share and a lower estimate of -$0.8.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. RYTM’s latest balance sheet shows that the firm has $294.86M in Cash & Short Term Investments as of fiscal 2021. There were $2.55M in debt and $43.43M in liabilities at the time. Its Book Value Per Share was $0.35, while its Total Shareholder’s Equity was $284.15M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RYTM is Buy with a score of 4.75.
